trial · primary record
ELVN-001
Chronic Myeloid Leukemia (CML)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 450 |
| Primary completion | 2033-07 |
| Primary endpoint | Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI |
| Registry ID | NCT07905183 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:10.609Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07905183
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.